I’m gonna miss vrtx Halloween and mooyov due to work kicking my ass this sucks
October 30, 2026 at 9:13 PM
I’m gonna miss vrtx Halloween and mooyov due to work kicking my ass this sucks
$VRTX: Top-Tier Franchise With Little Valuation Cushion
Latest score 66.2/100, down 4.6 after its latest report
2-yr score 68.7 - rank #23 of the S&P 500 (Top 10%)
AI lean: Cautiously Bullish
Analysis, not investment advice.
#VRTX #stocks #investing #StockMarket #earnings #SP500
Latest score 66.2/100, down 4.6 after its latest report
2-yr score 68.7 - rank #23 of the S&P 500 (Top 10%)
AI lean: Cautiously Bullish
Analysis, not investment advice.
#VRTX #stocks #investing #StockMarket #earnings #SP500
VRTX: Top-Tier Franchise With Little Valuation Cushion | Deep500
A high-margin CF franchise and a widening pipeline, but the premium multiple already prices in much of the growth.
www.deep500.com
November 3, 2026 at 5:29 PM
$VRTX: Top-Tier Franchise With Little Valuation Cushion
Latest score 66.2/100, down 4.6 after its latest report
2-yr score 68.7 - rank #23 of the S&P 500 (Top 10%)
AI lean: Cautiously Bullish
Analysis, not investment advice.
#VRTX #stocks #investing #StockMarket #earnings #SP500
Latest score 66.2/100, down 4.6 after its latest report
2-yr score 68.7 - rank #23 of the S&P 500 (Top 10%)
AI lean: Cautiously Bullish
Analysis, not investment advice.
#VRTX #stocks #investing #StockMarket #earnings #SP500
VRTX | Vertex (NASDAQ):
🚨 ATH ALERT: VRTX hit new High: $563.00 (Prev. price: 559.79)
🚨 ATH ALERT: VRTX hit new High: $563.00 (Prev. price: 559.79)
October 30, 2026 at 3:29 PM
VRTX | Vertex (NASDAQ):
🚨 ATH ALERT: VRTX hit new High: $563.00 (Prev. price: 559.79)
🚨 ATH ALERT: VRTX hit new High: $563.00 (Prev. price: 559.79)
VRTX | Vertex (NASDAQ):
📉 Yesterday's Daily Top Movers DOWN - #4: VRTX moved DOWN by 4.05% close: 530.76 (prev. day: 553.15)
📉 Yesterday's Daily Top Movers DOWN - #4: VRTX moved DOWN by 4.05% close: 530.76 (prev. day: 553.15)
November 4, 2026 at 9:48 AM
VRTX | Vertex (NASDAQ):
📉 Yesterday's Daily Top Movers DOWN - #4: VRTX moved DOWN by 4.05% close: 530.76 (prev. day: 553.15)
📉 Yesterday's Daily Top Movers DOWN - #4: VRTX moved DOWN by 4.05% close: 530.76 (prev. day: 553.15)
VRTX | Vertex (NASDAQ):
🚨 ATH ALERT: VRTX hit new High: $568.50 (Prev. price: 563.00)
🚨 ATH ALERT: VRTX hit new High: $568.50 (Prev. price: 563.00)
November 2, 2026 at 4:17 PM
VRTX | Vertex (NASDAQ):
🚨 ATH ALERT: VRTX hit new High: $568.50 (Prev. price: 563.00)
🚨 ATH ALERT: VRTX hit new High: $568.50 (Prev. price: 563.00)
#$VRTX — Vertex Q3: revenue $3.44B, non-GAAP EPS $4.76 (GAAP $2.56).
CF franchise $3.27B; CASGEVY $99.2M, JOURNAVX $58.3M.
VRTX Stock Hub: Vertex Pharmaceuticals News, Kidney Trials and Crinetics
www.merlintrader.com/vertex-pharm...
CF franchise $3.27B; CASGEVY $99.2M, JOURNAVX $58.3M.
VRTX Stock Hub: Vertex Pharmaceuticals News, Kidney Trials and Crinetics
www.merlintrader.com/vertex-pharm...
November 4, 2026 at 2:52 PM
#$VRTX — Vertex Q3: revenue $3.44B, non-GAAP EPS $4.76 (GAAP $2.56).
CF franchise $3.27B; CASGEVY $99.2M, JOURNAVX $58.3M.
VRTX Stock Hub: Vertex Pharmaceuticals News, Kidney Trials and Crinetics
www.merlintrader.com/vertex-pharm...
CF franchise $3.27B; CASGEVY $99.2M, JOURNAVX $58.3M.
VRTX Stock Hub: Vertex Pharmaceuticals News, Kidney Trials and Crinetics
www.merlintrader.com/vertex-pharm...
#VRTX Vertex Reports Third Quarter 2026 Financial Results
https://www.stocktitan.net/news/VRTX/vertex-reports-third-quarter-2026-financial-tr6cum559bql.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/VRTX/vertex-reports-third-quarter-2026-financial-tr6cum559bql.html?utm_source=stocktitan-bluesky&utm_medium=social
www.stocktitan.net
November 2, 2026 at 9:01 PM
#VRTX Vertex Reports Third Quarter 2026 Financial Results
https://www.stocktitan.net/news/VRTX/vertex-reports-third-quarter-2026-financial-tr6cum559bql.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/VRTX/vertex-reports-third-quarter-2026-financial-tr6cum559bql.html?utm_source=stocktitan-bluesky&utm_medium=social
$VRTX Earnings Release 📝
· Revenue of 3.4B exceeds estimates by 13.0M, with 11.87% YoY growth.
· EPS of 19.03 exceeds estimates by 0.06, with 296.46% YoY growth.
Follow up here stocknear.com/stocks/VRTX
· Revenue of 3.4B exceeds estimates by 13.0M, with 11.87% YoY growth.
· EPS of 19.03 exceeds estimates by 0.06, with 296.46% YoY growth.
Follow up here stocknear.com/stocks/VRTX
November 2, 2026 at 9:04 PM
$VRTX Earnings Release 📝
· Revenue of 3.4B exceeds estimates by 13.0M, with 11.87% YoY growth.
· EPS of 19.03 exceeds estimates by 0.06, with 296.46% YoY growth.
Follow up here stocknear.com/stocks/VRTX
· Revenue of 3.4B exceeds estimates by 13.0M, with 11.87% YoY growth.
· EPS of 19.03 exceeds estimates by 0.06, with 296.46% YoY growth.
Follow up here stocknear.com/stocks/VRTX
Vertex Pharmaceuticals $VRTX reported Q3 2026 Adj EPS of $4.76, beating the $4.70 estimate by 1.3%. Revenue of $3.4B beat the $3.4B estimate by 0.4%.
https://fundspec.ai/s/VRTX/earnings
The day's biggest whale trades, ranked.
https://fundspec.ai/s/VRTX/earnings
The day's biggest whale trades, ranked.
November 2, 2026 at 9:05 PM
Vertex Pharmaceuticals $VRTX reported Q3 2026 Adj EPS of $4.76, beating the $4.70 estimate by 1.3%. Revenue of $3.4B beat the $3.4B estimate by 0.4%.
https://fundspec.ai/s/VRTX/earnings
The day's biggest whale trades, ranked.
https://fundspec.ai/s/VRTX/earnings
The day's biggest whale trades, ranked.
Amgen Options Flip Bullish as Biotech Peers Rally Into Earnings
ortex.news/articles/204863/amgen-option…
$AMGN $GILD $VRTX
ortex.news/articles/204863/amgen-option…
$AMGN $GILD $VRTX
November 3, 2026 at 2:18 PM
Amgen Options Flip Bullish as Biotech Peers Rally Into Earnings
ortex.news/articles/204863/amgen-option…
$AMGN $GILD $VRTX
ortex.news/articles/204863/amgen-option…
$AMGN $GILD $VRTX
Q3 results after close today, call 4:30 PM ET.
#$VRTX closed $558.88 Fri, above SMA50 ($523.21), above SMA200 ($479.21), RSI 68.
Hub: www.merlintrader.com/vertex-pharm...
Interactive chart, bull/bear scenarios: justcharts.merlintrader.com#VRTX
Not investment advice.
#$VRTX closed $558.88 Fri, above SMA50 ($523.21), above SMA200 ($479.21), RSI 68.
Hub: www.merlintrader.com/vertex-pharm...
Interactive chart, bull/bear scenarios: justcharts.merlintrader.com#VRTX
Not investment advice.
November 2, 2026 at 2:24 PM
Q3 results after close today, call 4:30 PM ET.
#$VRTX closed $558.88 Fri, above SMA50 ($523.21), above SMA200 ($479.21), RSI 68.
Hub: www.merlintrader.com/vertex-pharm...
Interactive chart, bull/bear scenarios: justcharts.merlintrader.com#VRTX
Not investment advice.
#$VRTX closed $558.88 Fri, above SMA50 ($523.21), above SMA200 ($479.21), RSI 68.
Hub: www.merlintrader.com/vertex-pharm...
Interactive chart, bull/bear scenarios: justcharts.merlintrader.com#VRTX
Not investment advice.
#$VRTX Q3 results Nov 2 after the close: revenue $3.44B (+12% y/y); FY26 revenue guidance raised to $13.15–13.25B; povetacicept PDUFA Nov 30.
Close $553.15: above SMA50, above SMA200, RSI 64.
Bull/bear scenarios on JC Just Charts: justcharts.merlintrader.com#VRTX
Not investment advice.
Close $553.15: above SMA50, above SMA200, RSI 64.
Bull/bear scenarios on JC Just Charts: justcharts.merlintrader.com#VRTX
Not investment advice.
November 3, 2026 at 7:44 AM
#$VRTX Q3 results Nov 2 after the close: revenue $3.44B (+12% y/y); FY26 revenue guidance raised to $13.15–13.25B; povetacicept PDUFA Nov 30.
Close $553.15: above SMA50, above SMA200, RSI 64.
Bull/bear scenarios on JC Just Charts: justcharts.merlintrader.com#VRTX
Not investment advice.
Close $553.15: above SMA50, above SMA200, RSI 64.
Bull/bear scenarios on JC Just Charts: justcharts.merlintrader.com#VRTX
Not investment advice.
VRTX | Vertex (NASDAQ):
🚨 VRTX broke above its ATH price this week but closed the week back below it. (prior ATH: 560.25, week high: 563.80, week close: 558.88)
🚨 VRTX broke above its ATH price this week but closed the week back below it. (prior ATH: 560.25, week high: 563.80, week close: 558.88)
October 31, 2026 at 11:43 AM
VRTX | Vertex (NASDAQ):
🚨 VRTX broke above its ATH price this week but closed the week back below it. (prior ATH: 560.25, week high: 563.80, week close: 558.88)
🚨 VRTX broke above its ATH price this week but closed the week back below it. (prior ATH: 560.25, week high: 563.80, week close: 558.88)
🟢 #$VRTX — Regulatory Designation
Atumelnant Orphan Drug Designation in CAH; Phase 3 Enrollment Completion Expected 1Q 2027
FDA, EMA and MHLW have granted Orphan Drug designation to atumelnant in CAH. The 150-patient Phase 3 trial is enrolling and dosing, with …
https://biostock.app/symbols/VRTX
Atumelnant Orphan Drug Designation in CAH; Phase 3 Enrollment Completion Expected 1Q 2027
FDA, EMA and MHLW have granted Orphan Drug designation to atumelnant in CAH. The 150-patient Phase 3 trial is enrolling and dosing, with …
https://biostock.app/symbols/VRTX
November 2, 2026 at 9:20 PM
🟢 #$VRTX — Regulatory Designation
Atumelnant Orphan Drug Designation in CAH; Phase 3 Enrollment Completion Expected 1Q 2027
FDA, EMA and MHLW have granted Orphan Drug designation to atumelnant in CAH. The 150-patient Phase 3 trial is enrolling and dosing, with …
https://biostock.app/symbols/VRTX
Atumelnant Orphan Drug Designation in CAH; Phase 3 Enrollment Completion Expected 1Q 2027
FDA, EMA and MHLW have granted Orphan Drug designation to atumelnant in CAH. The 150-patient Phase 3 trial is enrolling and dosing, with …
https://biostock.app/symbols/VRTX
🟢 #$VRTX — Regulatory Designation
FDA Fast Track Designation for VX-017 in T1D; Pivotal Development Planned 2027
FDA granted Fast Track designation to VX-017, an allogeneic stem cell-derived islet cell therapy for T1D. Vertex is prioritizing VX-017 over zimisle…
https://biostock.app/symbols/VRTX
FDA Fast Track Designation for VX-017 in T1D; Pivotal Development Planned 2027
FDA granted Fast Track designation to VX-017, an allogeneic stem cell-derived islet cell therapy for T1D. Vertex is prioritizing VX-017 over zimisle…
https://biostock.app/symbols/VRTX
November 2, 2026 at 9:20 PM
🟢 #$VRTX — Regulatory Designation
FDA Fast Track Designation for VX-017 in T1D; Pivotal Development Planned 2027
FDA granted Fast Track designation to VX-017, an allogeneic stem cell-derived islet cell therapy for T1D. Vertex is prioritizing VX-017 over zimisle…
https://biostock.app/symbols/VRTX
FDA Fast Track Designation for VX-017 in T1D; Pivotal Development Planned 2027
FDA granted Fast Track designation to VX-017, an allogeneic stem cell-derived islet cell therapy for T1D. Vertex is prioritizing VX-017 over zimisle…
https://biostock.app/symbols/VRTX
VERTEX PHARMACEUTICALS INC / MA #VRTX EARNINGS HIGHLIGHTS
🔹 Revenue: $3.44B
🔹 GAAP EPS: $2.58
FY2026 Guide:
🔹 Total revenue: $13.15 to $13.25 billion
🔹 PALSONIFY revenue: $40 to $50 million
🔹 Combined GAAP R&D, AIPR&: $7.15 to $7.2 billion
Other Q Metrics:
🔹 Net
https://financier.news/
🔹 Revenue: $3.44B
🔹 GAAP EPS: $2.58
FY2026 Guide:
🔹 Total revenue: $13.15 to $13.25 billion
🔹 PALSONIFY revenue: $40 to $50 million
🔹 Combined GAAP R&D, AIPR&: $7.15 to $7.2 billion
Other Q Metrics:
🔹 Net
https://financier.news/
November 2, 2026 at 9:07 PM
VERTEX PHARMACEUTICALS INC / MA #VRTX EARNINGS HIGHLIGHTS
🔹 Revenue: $3.44B
🔹 GAAP EPS: $2.58
FY2026 Guide:
🔹 Total revenue: $13.15 to $13.25 billion
🔹 PALSONIFY revenue: $40 to $50 million
🔹 Combined GAAP R&D, AIPR&: $7.15 to $7.2 billion
Other Q Metrics:
🔹 Net
https://financier.news/
🔹 Revenue: $3.44B
🔹 GAAP EPS: $2.58
FY2026 Guide:
🔹 Total revenue: $13.15 to $13.25 billion
🔹 PALSONIFY revenue: $40 to $50 million
🔹 Combined GAAP R&D, AIPR&: $7.15 to $7.2 billion
Other Q Metrics:
🔹 Net
https://financier.news/
VRTX — HOLD 🟡
Vertex Pharmaceuticals (VRTX) is rated HOLD as rich valuation leaves little margin for disappointment, even with strong free cash flow and a solid balance sheet. CF concentration remains the key risk, while new launches must keep scaling to justify the current multiple.
lf0.com ↗
Vertex Pharmaceuticals (VRTX) is rated HOLD as rich valuation leaves little margin for disappointment, even with strong free cash flow and a solid balance sheet. CF concentration remains the key risk, while new launches must keep scaling to justify the current multiple.
lf0.com ↗
November 2, 2026 at 1:52 PM
VRTX — HOLD 🟡
Vertex Pharmaceuticals (VRTX) is rated HOLD as rich valuation leaves little margin for disappointment, even with strong free cash flow and a solid balance sheet. CF concentration remains the key risk, while new launches must keep scaling to justify the current multiple.
lf0.com ↗
Vertex Pharmaceuticals (VRTX) is rated HOLD as rich valuation leaves little margin for disappointment, even with strong free cash flow and a solid balance sheet. CF concentration remains the key risk, while new launches must keep scaling to justify the current multiple.
lf0.com ↗
🚨 $VRTX
On November 2, 2026, Vertex Pharmaceuticals Incorporated issued a press release in which it reported its consolidated financial results for the three and nine months ended September 30, 2026. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and i...
On November 2, 2026, Vertex Pharmaceuticals Incorporated issued a press release in which it reported its consolidated financial results for the three and nine months ended September 30, 2026. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and i...
SEC Filing: VRTX
Click to view the official SEC document.
www.sec.gov
November 2, 2026 at 9:09 PM
🚨 $VRTX
On November 2, 2026, Vertex Pharmaceuticals Incorporated issued a press release in which it reported its consolidated financial results for the three and nine months ended September 30, 2026. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and i...
On November 2, 2026, Vertex Pharmaceuticals Incorporated issued a press release in which it reported its consolidated financial results for the three and nine months ended September 30, 2026. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and i...
I've been watching $VRTX. Vertex TACI-Fc 52% proteinuria drop via BAFF/APRIL; sharp focus, infection risk underpriced. Buy +30. quantatative analysi
November 1, 2026 at 7:06 PM
I've been watching $VRTX. Vertex TACI-Fc 52% proteinuria drop via BAFF/APRIL; sharp focus, infection risk underpriced. Buy +30. quantatative analysi
#$VRTX weekly close $558.88 (+6.7% w/w), above SMA50 $523.21 / above SMA200 $479.21, RSI 67.7. Support $484.08, resistance $563.80.
New hub updated: www.merlintrader.com/vertex-pharm...
New hub updated: www.merlintrader.com/vertex-pharm...
VRTX Stock: Vertex News, Kidney Trials & Crinetics
Vertex Pharmaceuticals stock news: renal evidence, the November FDA target and results call, Crinetics integration and $13.6B pre-close June resources.
www.merlintrader.com
November 1, 2026 at 12:10 AM
#$VRTX weekly close $558.88 (+6.7% w/w), above SMA50 $523.21 / above SMA200 $479.21, RSI 67.7. Support $484.08, resistance $563.80.
New hub updated: www.merlintrader.com/vertex-pharm...
New hub updated: www.merlintrader.com/vertex-pharm...
$VRTX's last eight prints averaged a ±6.15% move, each against what options priced — priced right or not? Every past print: https://varamir.com/q/VRTX/earnings?utm_source=bluesky&utm_medium=reply&utm_campaign=red-alert-aug26&utm_content=p10-vrtx-02
VRTX Earnings Date Nov 2, 2026 · Expected Move & Options — Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Inc (VRTX) earnings: next report date, the market-implied expected move, options open interest by expiry with the day-over-day change in puts and calls, linked exposure across disclosed suppliers and customers, and the eight-quarter record of implied versus realized moves. Nex
varamir.com
October 30, 2026 at 12:47 PM
$VRTX's last eight prints averaged a ±6.15% move, each against what options priced — priced right or not? Every past print: https://varamir.com/q/VRTX/earnings?utm_source=bluesky&utm_medium=reply&utm_campaign=red-alert-aug26&utm_content=p10-vrtx-02
Earnings this week:
Mon: $AAPL $PLTR $VRTX $MAR $EL
Tue: $AMD $AMGN $ANET $SHOP $PFE
Wed: $TM $ARM $QCOM $MCD $NVO
Thu: $COP $SONY $NET $ABNB $CI
Fri: $ENB $MRNA $HUM $HMC $OKLO
Mon: $AAPL $PLTR $VRTX $MAR $EL
Tue: $AMD $AMGN $ANET $SHOP $PFE
Wed: $TM $ARM $QCOM $MCD $NVO
Thu: $COP $SONY $NET $ABNB $CI
Fri: $ENB $MRNA $HUM $HMC $OKLO
November 1, 2026 at 5:33 PM
Earnings this week:
Mon: $AAPL $PLTR $VRTX $MAR $EL
Tue: $AMD $AMGN $ANET $SHOP $PFE
Wed: $TM $ARM $QCOM $MCD $NVO
Thu: $COP $SONY $NET $ABNB $CI
Fri: $ENB $MRNA $HUM $HMC $OKLO
Mon: $AAPL $PLTR $VRTX $MAR $EL
Tue: $AMD $AMGN $ANET $SHOP $PFE
Wed: $TM $ARM $QCOM $MCD $NVO
Thu: $COP $SONY $NET $ABNB $CI
Fri: $ENB $MRNA $HUM $HMC $OKLO
⏳ Later today: Berkshire Hathaway (A shares) (BRK.A), Apple (AAPL), Clorox (CLX), Diamondback Energy (FANG), Realty Income (O), Palantir (PLTR), Vertex (VRTX), Williams Companies (WMB)
🔒 Numbers & expected moves → Whisper (Pro)
Did EL's numbers surprise you? Tell us below 💬
🔒 Numbers & expected moves → Whisper (Pro)
Did EL's numbers surprise you? Tell us below 💬
November 2, 2026 at 3:04 PM
⏳ Later today: Berkshire Hathaway (A shares) (BRK.A), Apple (AAPL), Clorox (CLX), Diamondback Energy (FANG), Realty Income (O), Palantir (PLTR), Vertex (VRTX), Williams Companies (WMB)
🔒 Numbers & expected moves → Whisper (Pro)
Did EL's numbers surprise you? Tell us below 💬
🔒 Numbers & expected moves → Whisper (Pro)
Did EL's numbers surprise you? Tell us below 💬
Earnings to Watch Week of November 2 - 6, 2026
#AAPL #ADTN #AEHR #AEIS #BWXT #CALX #CBT #CHKP #CIFR #CLX #EL #FANG #FN #HLIT #ICHR #L #LSCC #MAR #ON #PAY #PLTR #RIG #ROKU #TEM #TSEM #UPWK #VRTX #ALAB #AMD #ANET #BKNG #CAR #CMT #CPNG #DOCN #DT #DUOL #IPGP #LDOS #MOD #MPC #MPLX #NVTS #PCOR #RVLV #SHOP
#AAPL #ADTN #AEHR #AEIS #BWXT #CALX #CBT #CHKP #CIFR #CLX #EL #FANG #FN #HLIT #ICHR #L #LSCC #MAR #ON #PAY #PLTR #RIG #ROKU #TEM #TSEM #UPWK #VRTX #ALAB #AMD #ANET #BKNG #CAR #CMT #CPNG #DOCN #DT #DUOL #IPGP #LDOS #MOD #MPC #MPLX #NVTS #PCOR #RVLV #SHOP
October 31, 2026 at 12:21 PM
